Isocitrate dehydrogenase (IDH)-wildtype glioblastoma is an aggressive brain tumor, characterized by heterogenous tumoral behavior, therapeutic responses, and survival outcomes.1 Identifying preoperative prognostic markers for stratifying patients with IDH-wildtype glioblastoma is crucial for optimizing therapeutic strategies, designing personalized therapies, and improving overall patient outcomes.2 Here, IDH1 is linked to brain neoplasm.